Yuhan (XKRX:000100) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:000100 Yuhan Corp XKRX:000100
78 GF Score
Price ₩82,700.00
GF Value ₩113,769.34
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Yuhan FFO?

FFO (Funds from operations) only applies to REITs.

XKRX:000100
78GF Score
Yuhan Corp XKRX:000100
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Yuhan (XKRX:000100) Overvalued in 2026?

Based on GuruFocus' analysis, Yuhan stock appears to be undervalued. The current stock price of ₩82,700.00 is trading 27.3% below its estimated GF Value™ of ₩113,769.34. GuruFocus considers Yuhan to be Modestly Undervalued.

Key valuation signals for XKRX:000100:

  • FFO:
  • GF Value™: ₩113,769.34 vs. price of ₩82,700.00 (27.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the XKRX:000100 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Yuhan Business Description

Other Exchanges 000105:Korea
Address 74 Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, KOR
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
78GF Score

Get the complete analysis for XKRX:000100

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩82,700.00
Price
₩113,769.34
GF Value